We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other top stocks to watch from Jim Cramer’s latest portfolio.

Jim Cramer in a latest program on CNBC said that pain is “inevitable” in the stock market as investors go through the volatility infused by the latest tariffs announced by the US government against China, Canada and Mexico. However, Cramer said investors should get used to this volatility and be ready for different situations.

“Commerce Secretary Howard Lutnick said in the last of his myriad interviews of the day that maybe the Canadian and Mexican tariffs could be partially rolled back, perhaps as soon as tomorrow. Yes, it is all that capricious, and you better get used to it if you’re going to own stocks,” Cramer said.

READ ALSO 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In

For this article, we picked 10 stocks Cramer has been talking about recently. With each company we have mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution.

Bristol-Myers Squibb Company (NYSE:BMY)

Number Of Hedge Fund Investors: 88

A caller recently asked Jim Cramer about his thoughts on Bristol-Myers Squibb Company (NYSE:BMY) Here is what Cramer said:

“Bristol Myers is the most attractive drug stock, other than Eli Lilly. I think COBENFY is going to be one of the largest drugs of all time because it’s going into schizophrenia. It’s a great drug for the brain, really incredibly hard. I do a lot of stuff. I can tell you that this company really has the silver bullet for schizophrenia, which is one of the worst diseases in the world. It can be expanded beyond that. It’s a multi-billion-dollar drug, and it is going to be great. While you wait, 4.5% yield, own Bristol Myers.”

Overall, BMY ranks 4th on our list of top stocks to watch from Jim Cramer’s latest portfolio. While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than BMY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.